Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure-Reference-Cited by-同舟云学术

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

Published:2012-03-06 Issue:6 Volume:157 Page:764-766
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Prébet Thomas,Gore Steven D.,Thépot Sylvain¹,Esterni Benjamin²,Quesnel Bruno¹,Beyne Rauzy Odile¹,Dreyfus François¹,Gardin Claude¹,Fenaux Pierre¹,Vey Norbert

Affiliation:

1. Groupe Francophone des Myelodysplasies; Bobigny; France

2. Departement d'Hematologie; Institut Paoli Calmettes; Marseille; France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09076.x/fullpdf

Reference10 articles.

1. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome;Bello;Cancer,2011

2. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia;Cheson;Journal of Clinical Oncology,2003

3. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies;Fandy;Blood,2009

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

5. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia;Fenaux;Journal of Clinical Oncology,2010

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression;Life;2024-02-27

2. Overview of the Management of Higher-Risk Myelodysplastic Syndromes;The Cancer Journal;2023-05

3. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia;Hematological Oncology;2023-04-22

4. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents;Current Hematologic Malignancy Reports;2023-04-13

5. Therapie der rezidivierten/refraktären akuten myeloischen Leukämie;Im Fokus Onkologie;2023-04